Table 1.
The baseline characteristics of the study participants
| Mean | Std. Deviation | |
|---|---|---|
| Age | 64.2 | 9.2 |
| Disease duration | 6.8 | 4.5 |
| Sex (male/female) n | 89 | 89 |
| Wearing off (+/-) n | 58 | 120 |
| Dyskinesia (+/-) n | 42 | 136 |
| Levodopa mg | 344.1 | 202.8 |
| Levodopa (+/-) n | 154 | 24 |
| Dopamine agonist levodopa equivalent dose (mg) [12] | 166.3 | 121.1 |
| Total levodopa equivalent dose (mg) [12]a | 592.0 | 317.6 |
| Unified Parkinson’s Disease Rating Scale | ||
| Part I | 0.7 | 1.2 |
| Part II | 5.6 | 3.9 |
| Part III | 15.7 | 8.4 |
| Part IV | 1.7 | 2.2 |
| Total | 23.7 | 11.8 |
| Modified Hoehn and Yahr stage | 2.1 | 0.6 |
| Parkinson’s disease Questionnaire-39 | ||
| Mobility | 10.4 | 9.1 |
| Activities of daily living | 5.2 | 5.1 |
| Emotional well-being | 6.0 | 4.4 |
| Stigma | 3.2 | 2.8 |
| Social support | 1.4 | 1.9 |
| Cognitions | 4.0 | 3.0 |
| Communication | 1.7 | 2.2 |
| Body discomfort | 2.5 | 2.6 |
| Total | 34.4 | 24.2 |
a: not including istradefylline and zonisamide